Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tryton gets CE mark approval for Side-Branch Stent
The Tryton Side-Branch Stent is a high performance cobalt chromium balloon-expandable coronary stent. Richard Davis, chief technology officer of Tryton, said: “CE Mark will allow us to bring
The Tryton Side-Branch Stent is a high performance cobalt chromium balloon-expandable coronary stent. Richard Davis, chief technology officer of Tryton, said: “CE Mark will allow us to bring
This acquisition is expected to significantly accelerate AMRI’s ability to make custom pilot scale intermediates in India, which is expected to commence in the Q2 of 2008. AMRI
The primary endpoint of the study was the sum of pain intensity differences between baseline and day 21. Nalbuphine ER (nalbuphine hydrochloride extended release) did not meet this
Orphan drug designation entitles VioQuest to seven years of marketing exclusivity for VQD-002 upon regulatory approval, as well as the opportunity to apply for grant funding from the
Under the terms of the agreement GlaxoSmithKline (GSK) will be granted an exclusive, worldwide license to develop, manufacture and commercialize Amira’s FLAP inhibitors, including AM103 and other compounds
Asmanex (mometasone furoate inhalation powder) is an inhaled corticosteroid (ICS). Continual use of Asmanex helps manage asthma symptoms in patients with persistent asthma. Additionally, its automatic dose counter
Psorent contains LCD (liquid carbonis distillate), which has shown efficacy against psoriasis symptoms in a novel, aesthetically advanced formulation and package that promotes high patient compliance. Psorent will
Hans Petersen, president and CEO of Traversa, said: “The technology has received an outstanding level of interest for use with human therapeutics, and as a high throughput screening
Retaspimycin hydrochloride is currently being evaluated in clinical trials for the potential treatment of a variety of solid tumor cancers, including gastrointestinal stromal tumors, non-small cell lung cancer,
Archus Orthopedics will use the venture loan to accelerate its growth and clinical development process. Jim Fitzsimmons, CEO at Archus, said: “GE Healthcare Financial Services’ in-depth knowledge of